Annals of Surgical Oncology

, Volume 22, Issue 4, pp 1160–1167 | Cite as

Improved Long-Term Outcomes After Resection of Pancreatic Adenocarcinoma: A Comparison Between Two Time Periods

  • Pablo E. Serrano
  • Sean P. Cleary
  • Neesha Dhani
  • Peter T. W. Kim
  • Paul D. Greig
  • Kenneth Leung
  • Carol-Anne Moulton
  • Steven Gallinger
  • Alice C. Wei
Pancreatic Tumors



Despite reduced perioperative mortality and routine use of adjuvant therapy following pancreatectomy for pancreatic ductal adenocarcinoma (PDAC), improvement in long-term outcome has been difficult to ascertain. This study compares outcomes in patients undergoing resection for PDAC within a single, high-volume academic institution over two sequential time periods.


Retrospective review of patients with resected PDAC, in two cohorts: period 1 (P1), 1991–2000; and period 2 (P2), 2001–2010. Univariate and multivariate analyses using the Cox proportional hazards model were performed to determine prognostic factors associated with long-term survival. Survival was evaluated using Kaplan–Meier analyses.


A total of 179 pancreatectomies were performed during P1 and 310 during P2. Perioperative mortality was 6.7 % (12/179) in P1 and 1.6 % (5/310) in P2 (p = 0.003). P2 had a greater number of lymph nodes resected (17 [0–50] vs. 7 [0–31]; p < 0.001), and a higher lymph node positivity rate (69 % [215/310] vs. 58 % [104/179]; p = 0.021) compared with P1. The adjuvant therapy rate was 30 % (53/179) in P1 and 63 % (195/310) in P2 (p < 0.001). By multivariate analysis, node and margin status, tumor grade, adjuvant therapy, and time period of resection were independently associated with overall survival (OS) for both time periods. Median OS was 16 months (95 % confidence interval [CI] 14–20) in P1 and 27 months (95 % CI 24–30) in P2 (p < 0.001).


Factors associated with improved long-term survival remain comparable over time. Short- and long-term survival for patients with resected PDAC has improved over time due to decreased perioperative mortality and increased use of adjuvant therapy, although the proportion of 5-year survivors remains small.


Overall Survival Adjuvant Therapy Distal Pancreatectomy Pancreatic Ductal Adenocarcinoma Survival Estimate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Pablo E. Serrano, Sean P. Cleary, Neesha Dhani, Peter T.W. Kim, Paul D. Greig, Kenneth Leung, Carol-Anne Moulton, Steven Gallinger, and Alice C. Wei have no conflicts of interest to disclose for this study. We attest that we have herein disclosed any and all financial or other relationships that could be construed as a conflict of interest and that all sources of financial support for this study have been disclosed.

Supplementary material

10434_2014_4196_MOESM1_ESM.docx (153 kb)
Supplementary material 1 (DOCX 153 kb)
10434_2014_4196_MOESM2_ESM.docx (142 kb)
Supplementary material 2 (DOCX 141 kb)
10434_2014_4196_MOESM3_ESM.docx (141 kb)
Supplementary material 3 (DOCX 141 kb)
10434_2014_4196_MOESM4_ESM.jpg (110 kb)
Supplementary material 4 (JPEG 109 kb)
10434_2014_4196_MOESM5_ESM.jpg (109 kb)
Supplementary material 5 (JPEG 108 kb)
10434_2014_4196_MOESM6_ESM.jpg (112 kb)
Supplementary material 6 (JPEG 112 kb)
10434_2014_4196_MOESM7_ESM.jpg (115 kb)
Supplementary material 7 (JPEG 114 kb)


  1. 1.
    Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery. JAMA. 1998;280:1747–51.CrossRefPubMedGoogle Scholar
  2. 2.
    Ghaferi AA, Osborne NH, Birkmeyer JD, Dimick JB. Hospital characteristics associated with failure to rescue from complications after pancreatectomy. J Am Coll Surg. 2010;211:325–30.CrossRefPubMedGoogle Scholar
  3. 3.
    Ghaferi AA, Birkmeyer JD, Dimick JB. Variation in hospital mortality associated with inpatient surgery. N Engl J Med. 2009;361:1368–75.CrossRefPubMedGoogle Scholar
  4. 4.
    McNulty NJ, Francis IR, Platt JF, Cohan RH, Korobkin M, Gebremariam A. Multi–detector row helical CT of the pancreas: effect of contrast-enhanced multiphasic imaging on enhancement of the pancreas, peripancreatic vasculature, and pancreatic adenocarcinoma. Radiology. 2001;220:97–102.CrossRefPubMedGoogle Scholar
  5. 5.
    Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009;16:1727–33.CrossRefPubMedGoogle Scholar
  6. 6.
    House MG, Yeo CJ, Cameron JL, et al. Predicting resectability of periampullary cancer with three-dimensional computed tomography. J Gastrointest Surg. 2004;8:280–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304:1073–81.CrossRefPubMedGoogle Scholar
  8. 8.
    Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–77.CrossRefPubMedGoogle Scholar
  9. 9.
    Kalser MH, Ellenberg SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120:899–903.CrossRefPubMedGoogle Scholar
  10. 10.
    Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–10.CrossRefPubMedGoogle Scholar
  11. 11.
    Winter JM, Brennan MF, Tang LH, et al. Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann Surg Oncol. 2012;19:169–75.CrossRefPubMedGoogle Scholar
  12. 12.
    He J, Ahuja N, Makary MA, et al. 2564 resected periampullary adenocarcinomas at a single institution: trends over three decades. HPB (Oxford). 2014;16:83–90.CrossRefGoogle Scholar
  13. 13.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.CrossRefPubMedGoogle Scholar
  14. 14.
    Riall TS, Nealon WH, Goodwin JS, Zhang D, Kuo YF, Townsend CM Jr, et al. Pancreatic cancer in the general population: Improvements in survival over the last decade. J Gastrointest Surg. 2006;10:1212–23; discussion 1223-1214.Google Scholar
  15. 15.
    Sohal DP, Walsh RM, Ramanathan RK, Khorana AA. Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy. J Natl Cancer Inst. 2014;106:dju011.Google Scholar
  16. 16.
    Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–81.CrossRefPubMedGoogle Scholar
  17. 17.
    Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.CrossRefPubMedGoogle Scholar
  18. 18.
    Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–03.CrossRefGoogle Scholar
  19. 19.
    Yu XJ. Nab-paclitaxel combined with gemcitabine as adjuvant therapy for pancreatic cancer after curative resection (No) [ identifier NCT02023021]. US National Institutes of Health,
  20. 20.
    UNICANCER. Trial comparing adjuvant chemotherapy with gemcitabine versus mFolfirinox to treat resected pancreatic adenocarcinoma. [ identifier NCT01526135]. US National Institutes of Health,
  21. 21.
    Kim EJ, Ben-Josef E, Herman JM, et al. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer. 2013;119:2692–700.CrossRefPubMedCentralPubMedGoogle Scholar
  22. 22.
    Barugola G, Partelli S, Crippa S, Capelli P, D’Onofrio M, Pederzoli P, et al. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. Am J Surg. 2012;203:,132–39.CrossRefPubMedGoogle Scholar
  23. 23.
    Katz MH, Marsh R, Herman JM et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013;20:2787–95.CrossRefPubMedGoogle Scholar
  24. 24.
    Leone F, Gatti M, Massucco P, et al. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience. Cancer. 2013;119:277–84.CrossRefPubMedGoogle Scholar
  25. 25.
    Edge SB, Byrd DR, Compton CC, et al. Exocrine and endocrine pancreas. AJCC cancer staging manual. 7th ed. New York: Springer; 2010:241–49.Google Scholar
  26. 26.
    Sobin LG, Wittekind C. TNM classification of malignant tumours. 7th ed. Oxford: Wiley; 2010.Google Scholar
  27. 27.
    Mills M. Introducing survival and event history analysis. 2011:81–93.Google Scholar
  28. 28.
    Simons JP, Ng SC, McDade TP, Zhou Z, Earle CC, Tseng JF. Progress for resectable pancreatic [corrected] cancer? A population-based assessment of US practices. Cancer. 2010;116:1681–90.CrossRefPubMedGoogle Scholar
  29. 29.
    Langer B. Role of volume outcome data in assuring quality in HPB surgery. HPB (Oxford). 2007;9:330–4.CrossRefGoogle Scholar
  30. 30.
    Marcaccio M, LB, Rumble B, Hunter A; Expert Panel on HPB Surgical Oncology. Hepatic, pancreatic and biliary tract (HPB) surgical oncology standards. 2006. Accessed 2 Oct 2014.
  31. 31.
    Simunovic M, Urbach D, Major D, et al. Assessing the volume-outcome hypothesis and region-level quality improvement interventions: pancreas cancer surgery in two Canadian provinces. Ann Surg Oncol. 2010;17:2537–44.CrossRefPubMedGoogle Scholar
  32. 32.
    Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567–79.CrossRefPubMedGoogle Scholar
  33. 33.
    Tomlinson JS, Jain S, Bentrem DJ, et al. Accuracy of staging node-negative pancreas cancer: a potential quality measure. Arch Surg. 2007;142:767–74; discussion 773-764.Google Scholar
  34. 34.
    Slidell MB, Chang DC, Cameron JL, et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol. 2008;15:165–74.CrossRefPubMedGoogle Scholar
  35. 35.
    Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT, et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg. 2009;13:1337–44.Google Scholar
  36. 36.
    Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358:1576–85.CrossRefPubMedGoogle Scholar
  37. 37.
    Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003;237:74–85.CrossRefPubMedCentralPubMedGoogle Scholar
  38. 38.
    Valle JW, Palmer D, Jackson R, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014;32:504–12.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2014

Authors and Affiliations

  • Pablo E. Serrano
    • 1
    • 2
  • Sean P. Cleary
    • 3
    • 6
  • Neesha Dhani
    • 4
    • 6
  • Peter T. W. Kim
    • 5
  • Paul D. Greig
    • 3
    • 6
  • Kenneth Leung
    • 3
  • Carol-Anne Moulton
    • 3
    • 6
  • Steven Gallinger
    • 3
    • 6
  • Alice C. Wei
    • 3
    • 6
    • 7
  1. 1.Department of SurgeryMcMaster UniversityHamiltonCanada
  2. 2.Department of Clinical Epidemiology and Biostatistics, Faculty of Health SciencesMcMaster UniversityHamiltonCanada
  3. 3.Department of Surgery, University Health NetworkUniversity of TorontoTorontoCanada
  4. 4.Department of Medical Oncology and HematologyUniversity of TorontoTorontoCanada
  5. 5.Department of SurgeryBaylor University Medical CenterDallasUSA
  6. 6.Princess Margaret Cancer Center, University Health NetworkTorontoCanada
  7. 7.Institute of Health Policy, Management and EvaluationUniversity of TorontoTorontoCanada

Personalised recommendations